Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of JDQ443 versus docetaxel in previously treated KRAS G12C-mutant advanced or metastatic non-small cell lung cancer
CTR20223005Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of opnurasib, docetaxel in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Aug 2023; status: completed.
02
Drugs
opnurasibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20223005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223005.